Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer.
Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer.
复制标题
DOI：
10.1586/14737159.2015.1094379
复制
发表时间：
2015
影响因子：
5.1
通讯作者：
Wong DT
中科院分区：
文献类型：
--
作者：
Lin CC;Huang WL;Wei F;Su WC;Wong DT
肺癌靶向治疗的进展使得能够检测基因突变，特别是EGFR的基因突变。分析在很大程度上取决于肿瘤组织活检的获取，这是侵入性的，并且由于肿瘤异质性或治疗期间通过获得性耐药性发生的变化，可能无法反映治疗时肿瘤的基因组谱。液体活检是一种检测癌细胞或肿瘤DNA证据的血液检查，由于其检测EGFR突变的能力而引起了相当大的兴趣，然而，其临床应用受到复杂的收集方法和对技术依赖性平台的需求的限制。最近，已经开发了用于在尿液或唾液样品中检测EGFR突变体的更简单的技术。本文综述了液体活检的进展，并讨论了其在肺癌临床应用的潜力。
Advances in target therapies for lung cancer have enabled detection of gene mutations, specifically those of EGFR. Assays largely depend on the acquisition of tumor tissue biopsy, which is invasive and may not reflect the genomic profile of the tumor at treatment due to tumor heterogeneity or changes that occur during treatment through acquired resistance. Liquid biopsy, a blood test that detects evidence of cancer cells or tumor DNA, has generated considerable interest for its ability to detect EGFR mutations, however, its clinical application is limited by complicated collection methods and the need for technique-dependent platforms. Recently, simpler techniques for EGFR mutant detection in in urine or saliva samples have been developed. This review focuses on advances in liquid biopsy and discusses its potential for clinical implementation in lung cancer.